Brian O Mahony/X
Apr 24, 2026, 14:29
Brian O Mahony: Clinical Management of Emicizumab and Rebalancing Agents
Brian O Mahony, CEO of Irish Haemophilia Society, former President of WFH and EHC, shared a post on X:
”Young WFH Congress 2026.
Table illustrating switching,bleed management,surgical management and washout periods for Emicizumab and the 3 rebalancing agents.”
Other posts featuring Brian O Mahony on Hemostasis Today.
-
Sep 22, 2026, 09:18Shamee Shastry: How Transfusion Medicine Research Is Evolving in India
-
Sep 22, 2026, 09:11Tarique Shahzad Chachar: Why Warfarin Remains the Gold Standard for Mechanical Heart Valves
-
Sep 22, 2026, 09:04Bianca Rocca: Thromboinflammatory Injury in Ischemic Limb Necrosis During Severe Shock
-
Sep 22, 2026, 09:01Ash Paul: Comparing Left Atrial Appendage Occlusion and Oral Anticoagulation
-
Sep 22, 2026, 08:50Emily Horner: Lipoprotein(a) Links Oxidized Phospholipids to Platelet Hyperactivity
-
Sep 22, 2026, 08:42Sally Mandour: Bone Marrow Needle Gauge Explained
-
Sep 22, 2026, 08:39Alessandro Sionis: Navigating Anticoagulation in Mechanical Circulatory Support
-
Sep 22, 2026, 08:28Raghavendra Rao: The Latest Research on Varicose Veins
-
Sep 22, 2026, 08:23Aravind Palraj: Three Essential Tests in Antiphospholipid Syndrome